Europe's Proteinmaxxing Trend: What it Means for Infant Formula Prices Today

Europe's "proteinmaxxing" trend, the drive to maximise daily protein intake, has pushed whey protein prices to record highs and is now feeding directly into higher infant formula costs across the European Union. Whey protein concentrate 80 (WPC80), the ingredient that gives infant formula its breast-milk-like protein profile, cost €11,733 per metric tonne in July 2025 and had climbed to €25,875 per metric tonne by July 2026, according to market intelligence platform Expana. For EU parents already managing tighter household budgets, this ingredient shock is arriving at the worst possible moment.

Introduction: Proteinmaxxing and the Rising Cost of Infant Formula

Proteinmaxxing describes the growing consumer obsession with hitting ever-higher daily protein targets, a trend amplified by fitness culture and the rise of GLP-1 weight-loss medications. As demand for concentrated whey protein has surged, EU infant formula manufacturers, who rely on the same ingredient, are being squeezed by input costs more than double what they paid a year earlier.

This is not a distant industry problem. Whey protein concentrate is a core input for standard, follow-on and hypoallergenic infant formulas sold across Germany, France, the Netherlands, Spain, Italy, Belgium, Sweden, Poland and every other EU member state. When its price more than doubles in twelve months, the pressure eventually reaches supermarket shelves. Analysts at Rabobank, in their Global Dairy Quarterly report covering Q1 2026, noted that whey markets have proven more resilient than other dairy categories, "supported by strong demand for high-protein products", a dynamic that shows no sign of reversing through the second half of 2026.

The Surging Demand for Whey Protein

Whey protein concentrate prices have risen sharply across the EU in 2026 because structural supply constraints have collided with a surge in demand from both the sports nutrition sector and GLP-1 users seeking to preserve muscle mass. The result is a market where cheese producers generate ample raw whey, but processors lack the ultrafiltration capacity to convert it into the high-purity concentrate infant formula requires.

Benchmark pricing confirms the scale of the move. DCA Market Intelligence tracked WPC80 at €26,450 per tonne at the end of May 2026, up from roughly €14,320 per tonne in late January 2026, itself already a historically elevated level. Two forces are driving this:

GLP-1 weight-loss medications (such as semaglutide-based drugs), which suppress appetite but also raise the risk of muscle loss, have pushed millions of new users towards high-protein diets and supplements to preserve lean mass.
Broader "proteinmaxxing" consumer culture, which has moved concentrated whey from a niche gym-goer product into a mainstream ingredient found in everyday foods, from fortified coffee to snack bars, intensifying competition for the same limited supply that infant formula makers depend on.

Because ultrafiltration capacity cannot be expanded quickly, this is a structural shortage rather than a temporary price spike, meaning elevated whey costs are likely to persist well into 2027.

Impact on Infant Formula Manufacturing Costs

Infant formula manufacturers are absorbing whey costs that have more than doubled in a year, and industry voices warn that current price levels are becoming economically unsustainable to sustain without passing costs to consumers. Whey protein is not an interchangeable ingredient in infant nutrition: it is specifically used to adjust the whey-to-casein ratio so formula more closely mimics human breast milk and remains easier for infants to digest, which means manufacturers have limited room to substitute cheaper proteins without reformulating products subject to strict EU infant nutrition regulations.

This cost pressure has compounded an already difficult year for EU infant formula supply chains. The sector spent early 2026 managing the fallout from a separate contamination crisis: arachidonic acid (ARA) oil, another key infant formula ingredient, was found to be contaminated with the toxin cereulide, triggering major recalls from manufacturers including Nestlé, Danone and Lactalis. The European Commission published Implementing Regulation (EU) 2026/459 on 25 February 2026, imposing a zero-tolerance policy requiring ARA oil entering the EU market to be completely free of the toxin. Six EU member states, Austria, Belgium, Denmark, France, Luxembourg and Spain, reported infants with gastrointestinal symptoms linked to affected products. The result is a sector facing supply tightening on two fronts simultaneously: costlier whey protein and stricter, more expensive sourcing requirements for ARA oil.

What This Means for European Parents and Consumers

Rising ingredient costs are landing on households already coping with elevated food inflation across the EU. According to Eurostat's flash estimate published on 31 July 2026, euro area annual inflation rose to 2.9% in July 2026, up from 2.8% in June, with food, alcohol and tobacco inflation running at 1.2% for the month. Eurostat's Harmonised Index of Consumer Prices for baby food specifically stood at 132.34 points in November 2025, after touching a record high of 133.03 points in August 2025, indicating that baby food prices were already elevated before the latest whey protein surge fed through.

The social impact of this is concentrated among the households least able to absorb it. Infant formula is not discretionary spending: parents who cannot or do not breastfeed, including many in lower-income households, working parents returning to employment early, and families with medical or feeding difficulties, have no substitute product to switch to. A sustained rise in formula prices disproportionately affects single-parent households and lower-income families across member states such as Poland, Spain and parts of eastern and southern Europe, where formula already represents a larger share of household food spending than in wealthier northern EU states. Consumer groups in several member states have flagged early signs of "formula insecurity", where parents ration or dilute formula to stretch a tin further, a practice health authorities warn can compromise infant nutrition.

Industry Responses and Future Price Outlook

EU infant formula manufacturers are responding by reformulating products, diversifying protein sourcing, and lobbying Brussels for a stronger policy response, but near-term relief for consumers looks limited. The timing is politically awkward: the European Commission published its EU Protein Action Plan on 7 July 2026, setting a target to raise EU-grown protein used in animal feed from 25.8% to 35% by 2035. Crucially, the Plan sets no equivalent binding target or funding commitment for protein grown for direct human consumption, a gap that campaign group ProVeg International has publicly criticised as a "missed opportunity" at the exact moment human-food protein markets, including whey for infant formula, are under acute strain.

Compounding the picture, economists at Deutsche Bank, Natixis and Crédit Agricole expect the European Central Bank to raise interest rates again in September 2026 in response to persistent inflation and higher energy costs, which would further tighten household budgets just as formula manufacturers weigh whether to pass on ingredient costs. Manufacturers have so far tried to shield retail prices by absorbing margin compression, but with WPC80 costs more than double their July 2025 level, most analysts expect list price increases to reach EU supermarket shelves within two to three quarters if whey markets do not ease. For broader context on how EU inflation trends are affecting household budgets, see Baba International's finance coverage.

Conclusion: Navigating Nutritional Trends and Household Budgets

Europe's proteinmaxxing trend has created a genuine cost problem for infant formula, driven by a structural whey protein shortage that is unlikely to resolve quickly, layered on top of a separate ARA oil supply crisis and an EU policy framework that has not prioritised human-food protein. EU parents should expect infant formula prices to keep drifting upward through late 2026 and into 2027, even where retailers have so far held prices steady.

Readers can find further practical guidance on managing rising household costs via Baba International, and on infant nutrition and health topics through Baba International's health articles.

What EU Parents Can Do Now

Check national subsidy schemes: several EU member states offer income-tested support for infant nutrition costs; contact your local health or social affairs ministry to confirm eligibility before prices rise further.
Compare pharmacy and supermarket pricing: formula pricing can vary meaningfully between retail channels within the same country; comparing before bulk-buying can offset part of the increase.
Avoid diluting formula: never stretch formula by adding extra water to cut costs, as EU paediatric health authorities warn this can cause serious nutritional and health harm to infants.
Speak to a paediatrician before switching brands: if cost pressure prompts a switch to a cheaper formula, confirm with a health professional that the new product meets your infant's nutritional needs.
Monitor Eurostat's monthly HICP releases: tracking the baby food index can help households anticipate further price movements and time larger purchases accordingly.

Baba International Editorial Team

Our editorial team specialises in UK and EU personal finance, health policy, and economic analysis. All content is researched using authoritative sources including the ONS, NHS, Bank of England, ECB, and Eurostat.

Frequently Asked Questions

Why is proteinmaxxing affecting infant formula prices in the EU?

Proteinmaxxing has sharply increased demand for concentrated whey protein, the same ingredient EU manufacturers use to adjust infant formula's protein ratio to resemble breast milk. Whey protein concentrate 80 prices more than doubled between July 2025 and July 2026, according to market data from Expana, and manufacturers are struggling to absorb that cost without raising retail prices.

How much have whey protein prices risen in Europe in 2026?

Whey protein concentrate 80 rose from €11,733 per tonne in July 2025 to €25,875 per tonne in July 2026, with DCA Market Intelligence separately recording a benchmark of €26,450 per tonne at the end of May 2026, up from around €14,320 per tonne in late January 2026.

Is the EU doing anything about rising infant formula costs?

The European Commission's EU Protein Action Plan, published on 7 July 2026, focuses on raising EU-grown protein for animal feed rather than human food, drawing criticism from groups such as ProVeg International. Separately, the Commission introduced stricter EU-wide safety rules for ARA oil in February 2026 following contamination recalls, which has added further cost pressure to infant formula supply chains.

Will infant formula prices keep rising across the EU?

Most market analysts expect prices to keep drifting upward through late 2026 and into 2027, because the whey protein shortage is structural rather than temporary, driven by limited ultrafiltration processing capacity that cannot expand quickly enough to meet demand.